Opinion
Video
Treatment Sequencing With Androgen Receptor-Targeted Therapies for mCRPC
Author(s):
Key opinion leaders discuss considerations for sequencing androgen receptor-targeted therapies in metastatic castration-resistant prostate cancer, evaluating their benefits in first-line versus second-line treatment settings.
Video Player is loading.
When treating with androgen receptor-targeted therapies, what are some of the considerations to make towards the sequencing of these agents and weighing their benefits in first line versus second line?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Approaching Corticosteroid Selection With Abiraterone in Patients With High-Risk Localized or Locally Advanced Prostate Cancer
Incorporating Micronized Abiraterone and Low-Fat Meal Dosing: Monitoring Efficacy and Tolerability
The Growing Call for Combination Therapy in NMIBC Treatment
Optimizing NMIBC Treatment Through Sequencing and Patient Preference
Managing Abiraterone Intolerance: Alternative Dosing Strategies in Practice
Decision-Making and Multidisciplinary Counseling for Nodal Involvement on PSMA PET
Rethinking First-Line Treatments: Will BCG Continue to Be the Standard in NMIBC?
In the Pipeline: Novel Treatment Delivery Methods for NMIBC
RX Review: Implementing mitomycin for LG-IR-NMIBC in clinical practice
RX Review: TURBT vs chemoablation for low-grade, intermediate-risk NMIBC
Related Content
